Relapsed Acute Lymphoblastic Leukemia (ALL) | Relapsed AML (Acute Myeloid Leukemia)
LEUKEMIA (BLOOD CANCER)
Share
Last Updated : 2/8/2010
Bharat R Agarwal
More..
Relapse- ALL
Relapse may occur during or after completion of therapy and may occur in the bone marrow, testes or CNS. Allogenic bone marrow transplant should be considered in early relapse in therapy or within 6 months of termination of therapy or late marrow relapse with high tumor load as indicated by a peripheral blast count of 10,000/ul or more. For patients with late relapse (> 36 months in remission), a primary chemotherapy approach should be considered with bone marrow transplantation reserved for a subsequent marrow relapse.

AML - Relapse
Various statistical studies show that median duration of complete remission is 12 - 18 months with some form of intensive post - remission therapy. There is 25 - 50% chance of 3 - 5 year disease free interval in selected studies. Relapses are rare after 4 - 5 years. However, prognosis for a child with recurrent or progressive AML is poor. The long term survival rates after BMT is 45 - 50% (first remission), 25 - 30% (second remission), 15 - 20% (in relapse). However, the mortality rate after BMT is approximately 25 - 50%. The major causes of morbidity and mortality are infection and bleeding due to pancytopenia.



Contributor Information and Disclosures

Bharat R Agarwal
Pediatric Hematologist- Oncologist, Division of Pediatric Hem-Onco, B.J. Wadia Hospital for Children, Mumbai, India


First Created : 2/2/2001
Last Updated : 2/8/2010

References

Advertisements by :    Mega-CV by Aristo IndoIV by Sun Pharma
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.